Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study - Jongen, P J; Lehnick, D; Koeman, J (J Neurol, 2014)
et al.